Evidence map›Paper›PMID 41599016›Full record

ReviewPathogens (Basel, Switzerland)2025

Structure-Guided Design of Peptide Inhibitors Targeting Class I Viral Fusion Proteins.

Narendra Kumar Gonepudi, Harry Baffour Awuah, Wang Xu, Revansiddha H Katte, Maolin Lu

Abstract readReview
In one paragraph

Review in Pathogens (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Narendra Kumar GonepudiDepartment of Cellular and Molecular Biology, School of Medicine, University of Texas at Tyler Health Science Center, Tyler, TX 75708, USA.ORCID 0009-0005-3327-0116
Harry Baffour AwuahDepartment of Cellular and Molecular Biology, School of Medicine, University of Texas at Tyler Health Science Center, Tyler, TX 75708, USA.
Wang XuDepartment of Cellular and Molecular Biology, School of Medicine, University of Texas at Tyler Health Science Center, Tyler, TX 75708, USA.ORCID 0000-0003-4452-9240
Revansiddha H KatteDepartment of Cellular and Molecular Biology, School of Medicine, University of Texas at Tyler Health Science Center, Tyler, TX 75708, USA.ORCID 0000-0002-3844-8797
Maolin LuDepartment of Cellular and Molecular Biology, School of Medicine, University of Texas at Tyler Health Science Center, Tyler, TX 75708, USA.

Funding

The role of conformational dynamics of enveloped virus spike proteins in cell entryR35GM151169 · NIGMS · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI Maolin Lu · 2023 to 2026
$1.5M
Probing real-time conformational dynamics and allosteric cooperativity of the HIV-1 envelope glycoprotein during virus entryR01AI181600 · NIAID · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI Maolin Lu · 2024 to 2026
$1.3M
National Institute of Allergy and Infectious Diseases R01AI181600NIAID NIH HHS R01 AI181600NIGMS NIH HHS R35 GM151169NIGMS NIH HHS R35GM151169
6 · The paper itself

Abstract

Viral fusion proteins are indispensable mediators of viral entry that orchestrate the fusion of viral and host membranes, making them primary targets for antiviral interventions. Class I fusion proteins, displayed on the surface of enveloped viruses (such as HIV-1, RSV, SARS-CoV-2, Nipah, influenza, and Ebola viruses), share conserved structural features, including the fusion peptide or loop and heptad repeat regions. These elements are essential for the formation of the post-fusion six-helix bundle during membrane fusion. Peptide inhibitors that mimic heptad repeat motifs have consequently emerged as an effective strategy for blocking the fusion process. This review summarizes design strategies for such inhibitors and highlights how sequence and structural insights have enabled their optimization via α-helical stabilization, hydrocarbon stapling, lactam bridges, lipid conjugation, macrocyclization, and multivalency. Using representative examples across major viral systems, this review illustrates how these strategies have led to the development of potent, stable, and even broad-spectrum antiviral peptides. This review provides insights to guide the rational design of next-generation peptide-based fusion inhibitors targeting viral membrane fusion.

Indexed as

Antiviral AgentsDrug DesignPeptidesViral Fusion Protein InhibitorsViral Fusion ProteinsHumansVirus InternalizationAntiviral AgentsPeptidesViral Fusion Protein InhibitorsViral Fusion Proteinsclass I fusionfusion inhibitorspeptidesstructureviral fusion protein

Identifiers

PMID41599016
PMCPMC12845173

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.